Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Apr 11;14(1):71.
doi: 10.1186/s13287-023-03295-7.

Research progress of engineered mesenchymal stem cells and their derived exosomes and their application in autoimmune/inflammatory diseases

Xueqing Zhu #  1 , Dan Ma #  2 , Baoqi Yang  2 , Qi An  2 , Jingwen Zhao  2 , Xinnan Gao  2 , Liyun Zhang  3
Affiliations
Review

Research progress of engineered mesenchymal stem cells and their derived exosomes and their application in autoimmune/inflammatory diseases

Xueqing Zhu et al. Stem Cell Res Ther. .

Abstract

Autoimmune/inflammatory diseases affect many people and are an important cause of global incidence and mortality. Mesenchymal stem cells (MSCs) have low immunogenicity, immune regulation, multidifferentiation and other biological characteristics, play an important role in tissue repair and immune regulation and are widely used in the research and treatment of autoimmune/inflammatory diseases. In addition, MSCs can secrete extracellular vesicles with lipid bilayer structures under resting or activated conditions, including exosomes, microparticles and apoptotic bodies. Among them, exosomes, as the most important component of extracellular vesicles, can function as parent MSCs. Although MSCs and their exosomes have the characteristics of immune regulation and homing, engineering these cells or vesicles through various technical means, such as genetic engineering, surface modification and tissue engineering, can further improve their homing and other congenital characteristics, make them specifically target specific tissues or organs, and improve their therapeutic effect. This article reviews the advanced technology of engineering MSCs or MSC-derived exosomes and its application in some autoimmune/inflammatory diseases by searching the literature published in recent years at home and abroad.

Keywords: Autoimmune diseases; Exosomes; Genetic engineering; Mesenchymal stem cells; Surface modification; Tissue engineering.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Technologies for engineering MSCs or MSC-exos. MSCs or MSC-exos can be modified by genetic engineering, surface modification and tissue engineering. Genetic engineering includes viral and nonviral methods. In addition, gene editing technology can also be used to achieve accurate editing of target genes. Surface modification includes covalent and noncovalent modifications. In addition, MSCs and MSC-exos can be modified with tissue engineering technology in combination with biological scaffold materials. In the treatment of autoimmune diseases, engineered MSCs or MSC-exos can further improve their targeted homing in patients to better play the role of tissue repair and immunomodulation. Created by myself
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Marton LT, Barbalho SM, Sloan KP, Sloan LA, Goulart RA, Araújo AC, et al. Curcumin, autoimmune and inflammatory diseases: going beyond conventional therapy—a systematic review. Crit Rev Food Sci Nutr. 2022;62(8):2140–2157. doi: 10.1080/10408398.2020.1850417. - DOI - PubMed
    1. Zhernakova A, Withoff S, Wijmenga C. Clinical implications of shared genetics and pathogenesis in autoimmune diseases. Nat Rev Endocrinol. 2013;9(11):646–659. doi: 10.1038/nrendo.2013.161. - DOI - PubMed
    1. Wang L, Wang FS, Gershwin ME. Human autoimmune diseases: a comprehensive update. J Intern Med. 2015;278(4):369–395. doi: 10.1111/joim.12395. - DOI - PubMed
    1. Park Y, Kwok SK. Recent advances in cell therapeutics for systemic autoimmune diseases. Immune Netw. 2022;22(1):e10. doi: 10.4110/in.2022.22.e10. - DOI - PMC - PubMed
    1. Bays AM, Gardner G. Pharmacologic therapies for rheumatologic and autoimmune conditions. Med Clin North Am. 2016;100(4):719–731. doi: 10.1016/j.mcna.2016.03.001. - DOI - PubMed

Publication types